AstraZeneca (AZN) says “positive” full results from the BATURA Phase IIIb trial showed the company’s anti-inflammatory reliever rescue therapy, Airsupra, demonstrated statistically significant and clinically meaningful improvements in all primary and secondary endpoints compared to albuterol in patients with mild asthma. The trial measured as-needed Airsupra compared to as-needed albuterol. The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbation by 47% when compared with albuterol alone, Astra said in a statement. “The overwhelming efficacy of Airsupra at a pre-specified interim analysis led to the early stop of the BATURA trial as recommended by the Independent Data Monitoring Committee,” the company added. Craig LaForce, Medical Director of North Carolina Clinical Research, said: “The unprecedented BATURA trial results provide an opportunity to change 50 years of clinical practice in asthma.”

Confident Investing Starts Here:

Easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on AZN:

Disclaimer & DisclosureReport an Issue

Soros buys JPMorgan, exits Alibaba in Q1 U.S. biotech companies debate relocating trials outside U.S., Reuters reports Trump’s drug-price crackdown may lead to minor concessions, WSJ reports JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’ Pharma Stocks Rally despite Trump’s Plan to Cut Drug Prices

View Comments